Quotient Sciences has been recognized as a finalist for a special category award, "Best Innovative Approach to Technology and Process Execution," in the 2025 CDMO Leadership Awards. This additional award nomination highlights our unwavering commitment to providing innovative solutions and exceptional service within the contract development and manufacturing organization (CDMO) sector.
Last month, Quotient Sciences was recognized as a 2025 CDMO Leadership Awards winner in the category of Small Molecule Dosage Form – Global, and a finalist for the opportunity to win a champion award in the same category.
As part of the 2025 CDMO Leadership Awards, Outsourced Pharma asked the surveyed sponsors to identify top CDMOs in specific categories in order to determine these additional awards. The categories included: Best Scientific Expertise, Best On-Time Delivery, Best Seamless Delivery Across Phases, Best Innovative Approach to Technology and Process Execution, Best Manufacturing Capabilities, Best Facilities, Best Quality Management Systems.
These categories created the new "Best In" awards for 2025 to recognize additional qualities sponsors value when selecting a partner. Nominees along with Quotient Sciences in the "Best Innovative Approach to Technology and Process Execution" category include:
- Quotient Sciences
- AGC Pharma Chemicals
- MilliporeSigma
- WuXi Biologics
- WuXi STA
The CDMO Leadership Awards recognize the best contract development and manufacturing organizations (CDMOs) across global and regional categories. Winners will be honored at an award ceremony taking place tomorrow in New York City.